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Abstract
Background: Mortality among HIV-infected children in developing countries remains high after
serious bacterial infections despite the use of antibiotics. Intravenous immunoglobulin (IVIG) has
been used as an adjuvant therapy to treat these infections, but little data exists regarding its efficacy,
and previous studies have focused on IVIG as a prophylactic agent. We examined the impact of IVIG
as an adjuvant therapy in reducing mortality and length of hospital stay in HIV-infected children with
serious bacterial infections.
Methods: This retrospective study focused on pediatric admissions at a large urban hospital
between 2002 and 2006. Children between the ages of one month and nine years of age with
laboratory confirmed HIV-status, serious bacterial infection, no prior exposure to IVIG, and a
hospital length of stay of 5 days or more, were eligible for inclusion.
Results: A total of 140 children (median age 1.2 years) met inclusion criteria; lower respiratory
tract infection was diagnosed in 94 (67%) of the children, while 74 (53%) had bacterial sepsis. Fifty-
four (39%) children were receiving antiretroviral therapy and 39 (28%) were receiving tuberculosis
treatment. Overall 73 (52%) were treated with IVIG, with the majority (74%) of children receiving
a single dose. Thirteen (9%) died during their hospital admission. In crude analysis IVIG was
significantly associated with increased mortality was (Odds Ratio (OR): 5.8; 95% Confidence
Interval (CI): 1.2–27.1) and this association was weakened by adjustment for other predictors of
mortality (OR 4.3, 95% CI 0.7–27.9, p = 0.123). IVIG use was also associated with longer hospital
stays.
Conclusion: Administration of one to three doses of IVIG during the acute phase of illness does
not appear to reduce mortality or the length of hospital stays in HIV-infected children with serious
bacterial infections. However, the retrospective nature of this study makes confounding by
indication difficult to control and further studies regarding the timing, dosing, and method of
administration are required. Nonetheless the routine use of IVIG in resource-limited settings
should be carefully considered given its high cost.
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Background
With 2.3 million children living with HIV worldwide in
2006 [1], the virus is a particular health threat to children
in underdeveloped settings. South Africa has been heavily
affected by the epidemic: in 2005, 30% of pregnant
women in South Africa were HIV-infected and an esti-
mated 240,000 children were infected from mother to
child transmission. This number is expected to increase in
the coming years [2], placing additional strain on an
already over-burdened health system.
Infectious diseases are the leading cause of death among
HIV-infected children in South Africa and many other
developing countries, where as much as two-thirds of all
under-5 deaths may be directly or indirectly related to HIV
[3]. HIV-infected children are at significant risk of devel-
oping bacteremia and pneumonia, which are the most
common causes of mortality among the children requir-
ing hospital admission in South Africa [4-6].
The high mortality from infectious diseases in HIV-
infected children despite intravenous (IV) antibiotic ther-
apy has led to a search for adjuvant therapies such as intra-
venous immunoglobulin (IVIG). IVIG is an important
component in treating some immunodeficiencies as well
as autoimmune diseases [7]. For these diseases, immu-
noglobulin supplementation has several beneficial effects
including primary antibody replacement, immune system
modulation, suppression of auto-antibodies, and target-
ing of bacterial super-antigens [8,9]. Unfortunately, the
theoretical benefits of IVIG administration to HIV-
infected individuals have not been well-supported in the
clinical setting. Two randomized controlled trials were
unable to demonstrate any reduction in mortality from
the prophylactic use of IVIG against serious bacterial
infections, although some reduction in the number of
hospitalizations and infections were seen [10,11].
The role of IVIG in therapeutic treatment of acute infec-
tions in other pediatric populations appears somewhat
promising, although no studies have been done specifi-
cally in HIV-infected children. One prospective study
found that therapeutic IVIG was strongly associated with
shorter stays in a pediatric ward as well as decreased com-
plications and mortality regardless of HIV status [12].
Meta-analyses have demonstrated some therapeutic bene-
fit in treating sepsis in HIV negative neonates, but not
other age groups [13,14]. In the adult HIV-negative popu-
lation, there is conflicting evidence regarding the effect of
therapeutic benefits of IVIG on overall mortality [15,16].
Despite the mixed nature of available data, IVIG contin-
ues to be used in conjunction with antibiotics to treat bac-
terial infections in some settings, particularly in HIV-
infected children. However, the high cost of IVIG coupled
with supply shortages due to increasing off-label use have
resulted in calls for better guidelines and further research
[7,17,18].
To our knowledge, no study has evaluated IVIG as adjunct
treatment for serious bacterial infections in HIV-infected
children, although its use for sepsis prevention has been
evaluated. We analyzed the impact of therapeutic IVIG
administration on clinical outcomes among HIV-infected
children hospitalized for serious bacterial infections in
Cape Town, South Africa.
Methods
Study design and population
We conducted a retrospective cohort study of all HIV-
infected pediatric admissions at an urban public sector
hospital in Cape Town between January 2002 and June
2006. Over 50% of all admissions to the ward are HIV-
infected; the most common presenting conditions were
acute gastroenteritis or lower respiratory tract infections.
The referral population is a largely black African popula-
tion living in rapidly growing settlements with residents
of predominantly low socioeconomic status.
All children between one month and nine years of age
with laboratory confirmed HIV-status, a diagnosis of bac-
terial sepsis, bacterial pneumonia, and/or meningitis, no
prior exposure to IVIG, and a hospital length of stay of 5
days or more, were eligible for inclusion. Exclusion crite-
ria included established indications for IVIG such as
Kawasaki's disease, autoimmune hemolytic anemia, Guil-
lain-Barré syndrome, or idiopathic thrombocytopenia.
Data were collected from paper charts and cross-refer-
enced with pharmacy supply logs to confirm IVIG dosing.
For IVIG unexposed patients, the first admission for each
patient meeting inclusion criteria after January 1, 2002,
was chosen for analysis. For IVIG exposed patients, the
first admission where the child received IVIG was used.
Subsequent admissions were not examined.
Approval for this study was obtained from the University
of Cape Town Faculty of Health Sciences Research Ethics
Committee.
Measures
Basic demographic, laboratory and clinical information
were abstracted from patient charts using a standardized
abstraction form. Data were collected by a single individ-
ual. Data validity was checked by repeated blinded
abstraction on randomly selected charts.
Electrolyte, metabolic, liver function, and hematological
laboratory data was collected at four time points: admis-
sion, IVIG administration (or one week after admissionBMC Infectious Diseases 2008, 8:127 http://www.biomedcentral.com/1471-2334/8/127
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for the unexposed group), one week after IVIG adminis-
tration (or two weeks after admission for the unexposed
group), and discharge. If data was not available on the
exact date specified, lab values from the nearest date were
used. CD4/8 counts and percentages were not recorded as
part of this study due to the unavailability of these meas-
ures for most participants near the time of diagnosis.
Diagnoses of bacterial sepsis and bacterial pneumonia
were included based on clinical findings including chest
radiograph and blood cultures when available. A diagno-
sis of meningitis was included based on results of cerebro-
spinal fluid cultures collected from lumbar punctures.
Protein-energy malnutrition (PEM) was used to describe
clinical diagnoses of marasmus, Kwashiorkor or marasmic
Kwashiorkor.
Hospital length of stay was defined as a binary outcome
with a "long" stay defined as greater than the median
length of stay for all patients. Mortality was considered
only in the context of hospitalization. Patients who died
after discharge were excluded from mortality totals since
the date and cause of death could not be accurately dis-
cerned.
Antibiotics were analyzed individually and also grouped
by relative breadth of organism coverage. Thus, first-line
antibiotics were generally used as initial empiric coverage
for sensitive organisms whereas fourth-line antibiotics
were reserved for very resistant organisms or patients oth-
erwise refractory to treatment. First-line antibiotics were
defined as penicillin, ampicillin, gentamycin, ceftriaxone,
and cefuroxime. Second-line antibiotics were cloxacillin,
intravenous augmentin, cefazolin, and cefotaxime. Third-
line antibiotics were piperacillin, piperacillin plus tazo-
bactam, amikacin, cefipime, and ceftazadime. Fourth-line
antibiotics were ertapenem, imipenem, meropenem, and
vancomycin.
A modified PRISM III score was used to grade the severity
of illness in eligible children. The PRISM III is a validated
physiologically-based score for evaluating the risk of mor-
tality [19]. Because not all of the data required for calcu-
lating a complete PRISM III score were available upon
chart review, we developed a modified scoring system
based on percentages. A PRISM III score was calculated
from the available data for each patient and then divided
by the maximum possible score that the patient could
have received. When more than one lab value was appli-
cable, the most severe lab values were used to reflect the
greatest morbidity during the course of illness.
Analysis
Data analysis was conducted using Stata 9.0 (Stata Corpo-
ration, College Station, Texas, United States). Data were
described using means, medians and proportions; bivari-
ate analyses employed Students' t-tests, Wilcoxon rank-
sum tests, and chi-square tests, as appropriate. Multiple
logistic regression models were used to identify independ-
ent predictors of IVIG exposure, mortality, and hospital
length of stay. Models were constructed by sequential
addition of predictors and comparison of models using
the Akaike information criteria and the likelihood-ratio
chi-squared value. Variables were eligible to be examined
in the model if missing data on a particular covariate did
not reduce the number of observations in the model by
more than 10% of the total cohort size.
Results
Demographics
Of 247 patient records reviewed, 140 children met the
inclusion criteria for the cohort. The main reasons for
exclusion were lack of a qualifying diagnosis, uncon-
firmed HIV status, hospital length of stay less than 5 days,
use of IVIG for Kawasaki's disease and hemolytic anemia.
The demographic characteristics of the 140 included
patients are presented in Table 1.
In the cohort, 64 children (46%) were female, and the
median age was 1.2 years old (Interquartile Range (IQR):
0.5–2.3). The median weight on admission was 6.74 kg
(IQR 4.71–9.56). Only 66 subjects had birth weights
recorded, with a median weight of 2.79 kg (IQR 2.77–
3.02). A subset of children were on highly active antiretro-
viral therapy (HAART) and tuberculosis (TB) treatment
(39% and 28% respectively).
Hospital course
The median length of stay was 14.5 days (IQR 7–35).
Eighty-five children (61%) had at least one positive blood
culture during the hospital admission. Antibiotic use was
common, with 118 (84%) receiving 1st-line antibiotics,
42 (30%) receiving 2nd-line antibiotics, 51 (36%) receiv-
ing 3rd-line antibiotics, and 44 (31%) receiving 4th-line
antibiotics.
A diagnosis of lower respiratory tract infection was made
in 94 (67%) children, while 74 (53%) were diagnosed
with bacterial sepsis (proven or presumed). Only 4 (3%)
children were found to have bacterial meningitis. More
than one qualifying diagnosis for inclusion was found in
31 (22%) of the children.
Overall, 73 (52%) children were exposed to IVIG. Dosing
was always 400–500 mg/kg of IVIG given over 3–4 hours
of infusion. A single dose of IVIG was administered to 54
(74%) children, whereas 15 (21%) received two doses
and 4 (5%) received three doses. During the total observa-
tion time, 13 (9%) children died in hospital with the
remainder being discharged.BMC Infectious Diseases 2008, 8:127 http://www.biomedcentral.com/1471-2334/8/127
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Predicting IVIG exposure
Bivariate analysis revealed significant associations
between IVIG and mortality (p = 0.014), "long" hospital
stays (p < 0.001), presumed or proven bacterial sepsis (p
< 0.0001), a diagnosis of failure to thrive (p = 0.014), at
least one positive blood culture (p < 0.0001), and expo-
sure to 2nd -(p = 0.003), 3rd -(p < 0.0001), and 4th-line
antibiotics (p < 0.0001). Specific antibiotics were also
associated with IVIG, such as intravenous ampicillin (p =
0.012), cefotaxime (p < 0.001), vancomycin (p < 0.001),
Table 1: Demographic description of 140 admissions, overall and stratified by IVIG exposure
Characteristic Total cohort
n (%)
IVIG Unexposed
n (% of unexposed)
IVIG Exposed
n (% of exposed)
p-value
IVIG exposure (% of total cohort) 68 (48) 73 (52)
Gender
Males 76 (54) 37 (55) 39 (53) 0.831
Females 65 (46) 30 (45) 34 (47)
On HAART 54 (39) 21 (31) 33 (45) 0.092
On TB medication 39 (28) 17 (25) 22 (30) 0.496
Mortality 13 (9) 2 (3) 11 (15) 0.014
"Long" hospital stays 65 (46) 12 (18) 53 (73) < 0.001
Age at admission (yrs)
Median (IQR) 1.2 (0.5–2.3) 1.3 (0.6–2.5) 1.0 (0.4–2.1) 0.120
Weight at admission (kg)
Median (IQR) 6.7 (4.7–9.5) 7.3 (5.0–10.9) 6.0 (4.6–8.3) 0.039
Temp. at admission (°C)
Median (IQR) 37.3 (36.5–38.2) 37.4 (36.5–38.2) 37.3 (36.5–38.5) 0.812
Birth weight (kg)
Mean (95% CI) 2.9 (2.8–3.0) 3.0 (2.8–3.2) 2.8 (2.7–3.0) 0.321
Hospital length of stay (days)
Median (IQR) 15 (7–35) 8 (6–12) 30 (15–59) < 0.001
Modified PRISM percentage
Median (IQR) 11 (0–21) 6 (0–15) 14 (6–28) 0.004
Hemoglobin on admission
Median (IQR) 9.1 (8.1–10.3) 9.3 (8.4–10.5) 8.7 (8.0–10.2) 0.202
Diagnosis
Lower respiratory tract infection 94 (67) 50 (75) 44 (60) 0.062
Bacterial sepsis 74 (53) 24 (36) 50 (68) < 0.001
Bacterial meningitis 4 (3) 2 (3) 2 (3) 0.931
TB 40 (29) 16 (24) 24 (33) 0.239
TB meningitis 2 (1) 1 (2) 1 (1) 0.951
Gastroenteritis 54 (39) 21 (31) 33 (45) 0.092
Urinary tract infection 15 (11) 4 (6) 11 (15) 0.082
PEM 16 (11) 7 (10) 9 (12) 0.727
Fungal sepsis 4 (3) 0 (0) 4 (5) 0.052
Failure to thrive 29 (21) 8 (12) 21 (29) 0.014
Cultures
Any positive blood culture 85 (61) 29 (43) 56 (77) < 0.001
Positive E. coli blood culture 4 (3) 2 (3) 2 (3) 0.931
Positive S. pneumoniae blood culture 21 (15) 10 (15) 11 (15) 0.981
Positive C. albicans urine culture 7 (5) 0 (0) 7 (10) 0.009
Received
1st-line antibiotics 118 (84) 53 (79) 65 (89) 0.107
2nd-line antibiotics 42 (30) 12 (18) 30 (41) 0.003
3rd-line antibiotics 51 (36) 10 (15) 41 (56) < 0.001
4th-line antibiotics 44 (31) 5 (7) 39 (53) < 0.001
IV ampicillin 92 (66) 37 (55) 55 (75) 0.012
IV cefotaxime 32 (23) 6 (9) 26 (36) < 0.001
IV vancomycin 21 (15) 2 (3) 19 (26) < 0.001
IV piperacillin/tazobactam 21 (15) 4 (6) 17 (23) 0.004
IV fluconazole 14 (10) 0 (0) 14 (19) < 0.001
IV amphotericin 8 (6) 0 (0) 8 (11) 0.005BMC Infectious Diseases 2008, 8:127 http://www.biomedcentral.com/1471-2334/8/127
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and piperacillin/tazobactam (p = 0.004). Severity of ill-
ness, as measured by the modified PRISM score, was also
associated with IVIG exposure (p = 0.004).
The best-fit logistic regression predicting IVIG exposure is
presented in Table 2. Significant predictors were any pos-
itive blood culture regardless of organism (OR 4.3, 95%
CI 1.6–11.8), a diagnosis of failure to thrive (OR 5.0, 95%
CI 1.5–16.3), exposure to third-line (OR 4.0, 95% CI 1.4–
11.5) and fourth-line antibiotics (OR 10.3, 95% CI 2.9–
37.0), as well as intravenous ampicillin (OR 5.1, 95% CI
1.7–15.7) and cefotaxime (OR 6.2, 95% CI 1.7–22.5). The
modified PRISM percentage was not a significant predic-
tor of IVIG exposure in the multivariate analysis. Not
included in the model are several variables in the analysis
which were perfect predictors of IVIG exposure namely:
diagnosis of fungal culture-proven sepsis, exposure to
intravenous fluconazole, intravenous amphotericin, and
positive urine culture for Candida albicans.
Predicting mortality and hospital length of stay
The best-fit logistic regression models for predicting mor-
tality and hospital length of stays are presented in Table 3.
The unadjusted odds ratio of IVIG association with mor-
tality was 5.8 (95% CI 1.2–27.1). However, the associa-
tion became statistically non-significant after inclusion of
significant predictors of mortality (OR 4.3, 95% CI 0.7–
27.9). Significant predictors for mortality included expo-
sure to intravenous vancomycin (OR 7.2, 95% CI 1.5–
33.4), a diagnosis of PEM (OR 13.3, 95% CI 2.2–81.0),
and a positive E. coli blood culture (OR 20.7, 95% CI 1.1–
379.7). Being female was also significant for predicting
mortality (OR 7.0, 95% CI 1.3–38.7).
"Long" hospital stays were positively predicted by IVIG
exposure (OR 7.5, 95% CI 2.8–20.0) even after adjust-
ment for exposure to 3rd-line (OR 3.5, 95% CI 1.3–9.7)
and 4th-line antibiotics (OR 3.4, 95% CI 1.1–10.4). A pos-
itive blood culture for Streptococcus pneumoniae (OR 0.13,
95% CI 0.03–0.6) was protective against a "long" hospital
stay.
Discussion
Our analysis suggests that one to three doses of IVIG pro-
vides only limited therapeutic benefit in acutely treating
severe bacterial infections for HIV-infected children.
Patients who received IVIG had longer hospital stays and
a trend toward increased likelihood of mortality than
those who did not, even after controlling for severity of ill-
ness and concomitant antibiotic exposure. Although a
small benefit cannot be ruled out, the likelihood of a clin-
ically significant benefit from IVIG appears to be low.
Theoretically, IVIG might have provided similar benefits
in HIV-infection as seen in primary immunodeficiencies.
However, differences in disease mechanism may explain
why clinical outcomes have not been as significantly favo-
rable in HIV-infection. HIV-infection in children often
results in a relative hypergammaglobulinemia in compar-
ison with adults, likely secondary to abnormal B-cell acti-
vation [20,21]. Despite the high immunoglobulin G
(IgG) levels in children with HIV, measurement of these
levels does not appear to be a good marker for humoral
immune system functionality as these children often have
a decreased response to vaccines [22-24]. This suggests
that the poor antibody response is functional rather than
quantitative in nature and simply elevating circulating IgG
levels is insufficient to convey improved bacterial resist-
ance in children.
Differences in study populations make comparison with
other studies difficult. El-Nawawy et al. demonstrated that
mortality in patients who received IVIG was halved from
56 to 28 percent [12]. Meta-analyses have shown very lim-
ited benefit of treating neonates, and even then only in
lab-proven infection [13,16]. None of these studies distin-
guished between HIV-infected and non-infected children.
Thus far, the studies conducted on HIV-infected children
have only examined the role of IVIG as prophylaxis. The
NICHD trial showed increased time free of infections and
decreases in serious bacterial infections and acute hospi-
talizations [10]. The PACTG protocol 51 showed that IVIG
and zidovudine together reduced mild bacterial infections
and acute hospitalizations [11]. However, the benefits of
IVIG disappeared in children who also received daily cot-
rimoxazole. In both studies, mortality remained
unchanged.
Differences in the timing and dosing of IVIG also make
comparison across studies difficult. In this study, the
majority of participants received only a single dose of
400–500 mg/kg IVIG. This dose was given when patients
were significantly ill. Only two of the 21 trials included in
the meta-analysis by Pildal and Getzsche administered
IVIG in a single dose [15]. The other 19 trials administered
treatment at intervals or continuously over the course of
1.5 to 6 days. Those in the study by El-Nawawy, et al.,
received equal doses administered during the first 3 days
of admission [12]. Single doses of IVIG may be insuffi-
Table 2: Logistic regression model predicting IVIG exposure
Predictors Adjusted IVIG exposure OR (95% CI)
Any positive blood culture 4.3 (1.6–11.8)
Diagnosis of failure to thrive 5.0 (1.5–16.3)
3rd-line antibiotics 4.0 (1.4–11.5)
4th-line antibiotics 10.3 (2.9–37.0)
IV ampicillin 5.1 (1.7–15.7)
IV cefotaxime 6.2 (1.7–22.5)BMC Infectious Diseases 2008, 8:127 http://www.biomedcentral.com/1471-2334/8/127
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cient to provide protective effects, as it can take 4–6
months of infusion to reach a steady state [25]. The need
to reach adequate protective serum levels is supported by
the delay in treatment effect noted during the NICHD trial
[26].
There may be several reasons why IVIG as well as vanco-
mycin were associated with increased mortality. Late rec-
ognition of the severity of illness and delayed
administration of IVIG could explain why treated children
had longer hospital stays. In turn, long hospital stays lead
to an increased risk of nosocomial infection potentially
resistant to antibiotics and unaffected by IVIG.
Alternatively, many infections may have been viral or
mycobacterial, thus explaining the ineffectiveness of anti-
biotics. Of the 13 children who died in-hospital, 4 had
negative blood cultures for their entire stay. Excessive use
of antibiotics may also have contributed to the increased
mortality. The current practice in some settings, including
this one, is that children receive a full course of antibiotics
even if blood cultures are negative. This is due to concerns
about the poor sensitivity of cultures. The overuse of anti-
biotics in turn may lead to the development of resistant
organisms. A recent study in Tanzania found almost 14%
of pediatric admissions had laboratory-confirmed bacte-
rial sepsis despite two-thirds of them having received
prior antibiotic treatment [27]. Prolonged exposure to
broad spectrum antibiotics also increases the risk of devel-
oping fungal infections which are not easily recognized or
treated.
Mortality in the study cohort was also associated with
PEM. This is consistent with previous studies showing the
combination of malnutrition and HIV increases the likeli-
hood of mortality [28,29]. This suggests that preventative
care and ensuring adequate nutrition may help mitigate
the severity of illness and reduce mortality. However,
reducing mortality from malnutrition in the context of
HIV has been challenging and the interplay between vari-
ous contributing factors remains unclear [30,31].
There were several limitations to this study. Retrospective
studies cannot control which participants receive treat-
ment, resulting in confounding by indication. Children
who were more seriously ill and at greater risk of mortality
were also those most likely to receive IVIG. Although an
attempt to capture illness severity was done through a
modified PRISM percentage, it may not have been an ade-
quate indicator of severity. Nor has this modified score
been validated in other studies. In addition, insufficient
data on CD4 percentages and viral loads was available to
take into account the level of immunosuppression. In the
NICHD trial, only children with CD4 counts ≥ 200/mm3
benefited from IVIG prophylaxis [10]. Conducting a pro-
spective trial would address these limitations and allow
for better subgroup analysis. Also, a future comparison
between intravenous and subcutaneous administration
may be warranted. Subcutaneous administration has
become more commonplace due to its improved side
effect profile, equivalent benefit, and improved quality of
life, and in some cases lower costs [32]. Whether these
benefits would be seen in resource-limited settings
remains to be seen.
Conclusion
To our knowledge, this is the first study to evaluate IVIG
as adjunct treatment for bacterial sepsis in HIV-infected
children. Previous studies have focused on sepsis preven-
tion. Our findings suggest that one to three doses of IVIG
during the acute phase of illness may have minimal to no
therapeutic benefit in reducing mortality and is not asso-
ciated with decreased length of hospital stay in HIV-
infected children with serious bacterial infections. How-
ever, the retrospective nature of this study makes con-
founding by indication difficult to control. Further
research will be necessary regarding whether different tim-
ing, dosing, and/or methods of administration may prove
Table 3: Logistic regression models predicting mortality and hospital length of stay
Predictors Unadjusted Mortality OR 
(95% CI)
Adjusted Mortality OR 
(95% CI)
Unadjusted "Long" hospital 
stays OR (95% CI)
Adjusted "Long" hospital 
stays OR (95% CI)
IVIG exposure 5.8 (1.2–27.1) 4.3 (0.7–27.9) 12.1 (5.4–27.3) 7.5 (2.8–20.0)
IV vancomycin 7.2 (1.5–33.4)
Diagnosis of PEM 13.3 (2.2–81.0)
E. coli blood culture 20.7 (1.1–379.7)
Female 7.0 (1.3–38.7)
3rd-line antibiotics 3.5 (1.3–9.7)
4th-line antibiotics 3.4 (1.1–10.4)
Positive blood culture for 
S. pneumoniae
0.13 (0.03–0.6)BMC Infectious Diseases 2008, 8:127 http://www.biomedcentral.com/1471-2334/8/127
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more beneficial. The benefits seen by other studies suggest
earlier and/or longer administration of immunoglobulin
may be more effective. However, in limited-resource set-
tings, non-pharmacological improvements in disease pre-
vention, detection, and follow-up care should also be
strongly considered in reducing the significant morbidity
and mortality seen in young infants and children living
with HIV.
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